UPDATE: Cowen Starts Ambrx Biopharma (AMAM) at Outperform
Tweet Send to a Friend
(Updated - July 13, 2021 6:21 AM EDT)
Cowen analyst Phil Nadeau initiates coverage on Ambrx Biopharma (NYSE: AMAM) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Cowen analyst Phil Nadeau initiates coverage on Ambrx Biopharma (NYSE: AMAM) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
